TET2 was shown to acquire gain-of-function genetic alterations, especially in iso-citrate dehydrogenase 1 and 2 (IDH1 IDH2) in acute myelogenous leukemia (AML) [181]. This evidence concerns the gene IDH1 and acute myeloid leukemia.